AbbVie | ABBV

Stock Price
160.83
Daily Change
0.53 0.33%
Monthly
-4.02%
Yearly
9.71%
Q2 Forecast
160.71
Peers Price Chg Day Year Date
Eisai 6,793.00 104.00 1.55% -14.33% May/10
AbbVie 160.83 0.53 0.33% 9.71% May/10
Abbott 104.61 0.18 0.17% -4.94% May/10
ALKERMES 24.05 -0.21 -0.87% -22.87% May/10
Amgen 310.23 -3.04 -0.97% 33.55% May/10
AstraZeneca 12,370.00 38.00 0.31% 3.74% May/10
Biogen 221.52 -1.20 -0.54% -28.67% May/10
BioMarin Pharmaceutical 81.03 -0.69 -0.84% -15.05% May/10
Bristol-Myers Squibb 44.73 0.18 0.40% -35.25% May/10
Gilead Sciences 65.91 1.39 2.15% -16.25% May/10
GlaxoSmithKline 1,799.50 19.00 1.07% 24.55% May/10
J&J 150.03 0.15 0.10% -6.81% May/10
Eli Lilly 760.00 -10.88 -1.41% 74.49% May/10
Medtronic 84.00 0.36 0.44% -5.64% May/10
Merck 130.06 -0.11 -0.08% 10.64% May/10
Neurocrine Biosciences 136.70 -2.96 -2.12% 39.75% May/10
Novartis 92.32 1.78 1.97% -0.28% May/10
Pacira 29.42 -0.44 -1.47% -29.99% May/10
Pfizer 28.01 -0.20 -0.71% -25.47% May/10
Perrigo 30.71 -0.28 -0.90% -13.49% May/10
Ultragenyx Pharmaceutical 40.90 -0.32 -0.78% -13.18% May/10
Regeneron Pharmaceuticals 975.34 7.08 0.73% 30.82% May/10
Roche Holding 225.10 3.20 1.44% -20.30% May/10
Sanofi 94.33 1.15 1.23% -4.87% May/10
UCB 123.00 4.25 3.58% 45.32% May/10
United Therapeutics 264.27 -1.78 -0.67% 23.79% May/10
Vertex Pharmaceuticals 422.78 3.53 0.84% 20.66% May/10
Zoetis 169.15 0.90 0.53% -8.63% May/10

Indexes Price Day Year Date
US500 5223 8.59 0.16% 26.44% May/10

AbbVie traded at $160.83 this Friday May 10th, increasing $0.53 or 0.33 percent since the previous trading session. Looking back, over the last four weeks, AbbVie gained 4.02 percent. Over the last 12 months, its price rose by 9.71 percent. Looking ahead, we forecast AbbVie to be priced at 160.71 by the end of this quarter and at 154.57 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.